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Background: Intervention and treatment in Alzheimer’s disease dementia (AD-dementia) can be cost effective but
the majority of patients are not diagnosed in a timely manner. Technology is now available that can enable the
earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention
in the UK health care system. This study aimed to determine to what extent the timing of an intervention affects its
cost-effectiveness.
Methods: Using published data describing cognitive decline in the years prior to an AD diagnosis, we modelled
the effects on healthcare costs and quality-adjusted life years of hypothetical symptomatic and disease-modifying
interventions. Early and standard interventions were assumed to have equal clinical effects, but the early intervention
could be applied up to eight years prior to standard diagnosis.
Results: A symptomatic treatment which immediately improved cognition by one MMSE point and reduced in efficacy
over three years, would produce a maximum net benefit when applied at the earliest timepoint considered, i.e. eight
years prior to standard diagnosis. In this scenario, the net benefit was reduced by around 17% for every year that
intervention was delayed. In contrast, for a disease-modifying intervention which halted cognitive decline for one year,
economic benefits would peak when treatment effects were applied two years prior to standard diagnosis. In
these models, the maximum net benefit of the disease modifying intervention was fifteen times larger than that
of the symptomatic treatment.
Conclusion: Timeliness of intervention is likely to have an important impact on the cost-effectiveness of both
current and future treatments. Healthcare policy should aim to optimise the timing of AD-dementia diagnosis,
which is likely to necessitate detecting and treating patients several years prior to current clinical practice.
Keywords: Alzheimer’s disease, Dementia, Diagnosis, Treatment, Early intervention, Health economics, Cost-effectiveness,
Cholinesterase inhibitorsBackground
Dementia is estimated to affect 36 million people world-
wide, costing more than US $600 billion a year [1]. The
ageing demographics of both developed and developing na-
tions mean that its prevalence will double over the next
20 years [2]. Alzheimer’s disease dementia (AD-dementia)
is the most common form, estimated to account for 60 to
80% of cases [3]. An additional 5-42% of older adults [4]
meet criteria for mild cognitive impairment (MCI), a lesser
degree of impairment than dementia, which allows them to
continue to function independently [5].* Correspondence: andrew.blackwell@camcog.com
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unless otherwise stated.The current model of Alzheimer’s disease is of a
pathological process which starts in mid-life but remains
undetected until it causes dementia, at which time a
clinical diagnosis of AD-dementia can be made. Recent
revisions to diagnostic criteria define three stages of
Alzheimer’s disease, namely Alzheimer’s disease demen-
tia [6], MCI due to AD (MCI-AD) [7], and preclinical
AD [8]. Broadly speaking, the MCI and dementia stages of
AD can be determined by a combination of clinical assess-
ment and biomarkers, while detection of preclinical AD,
characterised by the absence of overt symptoms, requires
brain-related assays of disease progression [9-11]. Within
the MCI population a significant proportion have symp-
toms due to underlying AD pathology (MCI-AD [7]).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cognitive marker in those with MCI who progress to
AD-dementia, and each year around 15% of individuals
with amnestic (memory-impaired) MCI are diagnosed
with AD-dementia [5,9].
Technology now exists that can enable the earlier de-
tection of cognitive loss associated with incipient de-
mentia, offering the potential for earlier intervention in
the UK health care system ([12,13]). Timely detection
and intervention in AD-dementia can be cost-effective
because even though current treatments have limited ef-
ficacy, they nonetheless improve symptoms enough to
reduce healthcare costs and keep patients living in the
community for longer. Although the debate over cost-
effectiveness of current treatment is controversial, some
economic studies have estimated that timely treatment
is cost-effective [14]. A UK study based on 2007 costs
estimated that over ten years, timely detection and
treatment produced savings of £3600 (US $5508) in
direct costs and an additional £4150 ($6350) in indirect
costs (caregiver time) per patient [15]. Similar cost-
effectiveness has been established for other healthcare
systems, including the US [16]. Despite this, in the UK
as in other countries, the majority of people with AD-
dementia do not have a diagnosis, with up to three quarters
undiagnosed in some regions [17-19].
Improved public awareness of AD-dementia is driving
older adults who experience memory problems to seek
help at an increasingly early stage. At presentation, many
of these individuals may meet criteria for MCI-AD for
which, as yet, there are no licensed treatments [20].
There is considerable debate within the clinical and pub-
lic health communities as to the stage at which it is most
appropriate to assess and treat people who may have, or
be worried about, the early signs of AD-dementia. There
is generally little economic evidence about pre-dementia
stages of AD (MCI-AD) [21], but it is likely that re-
source use increases considerably in the years preceding
an AD diagnosis [22].
One key factor determining when detection and diag-
nosis programmes should be targeted is understanding
at what stage in disease the available interventions are
most clinically effective. Unfortunately, there is little data
on the size of clinical effect at different stages of disease
for even the most common treatments such as cholin-
esterase inhibitors. It is generally thought that these
interventions are more effective when used before wide-
spread pathological change has occurred [23-25], but
there is little evidence that they are effective in pre-
dementia stages such as MCI-AD [20,26].
A second major factor is economic: the extent to
which healthcare costs and quality of life are changed by
intervening at different points in the disease course. In
this study we aimed to assess the economic effects ofintervening in AD-dementia up to 9 years earlier than
that which currently occurs. In the absence of detailed
data comparing the efficacy of treatments at different
stages, we concentrated only on the economic impact
of applying (equally effective) interventions at different
points in the disease course. Because few treatments
are currently available, we modelled the effects of two
hypothetical interventions: one a modestly-effective symp-
tomatic treatment, the other a hypothetical disease-
modifying treatment (DMT) that halted cognitive decline
for a short period. These two scenarios were chosen as
simple and relatively conservative examples of the type
of intervention that might plausibly achieve widespread
adoption within a healthcare system such as the UK NHS
or US Medicare. In this way we aimed to quantify the ex-
tent to which the potential costs and savings from an
intervention for AD-dementia would be impacted by the
time of intervention.Methods
Data and cost assumptions
Our model was based on the reported natural history
of cognitive decline in the nine years preceding a diag-
nosis of Alzheimer’s disease (AD-dementia) [27] in a
longitudinal population-based study in the southwest
of France, the Paquid cohort [28]. In this study, cog-
nitive function was monitored in 1285 individuals
who were initially assessed as not being demented,
including 215 who were subsequently diagnosed with
dementia due to Alzheimer’s disease. These data are
therefore a description of the average cognitive decline
experienced during pre-diagnosis AD. With a mean
Mini Mental State Examination (MMSE) [29] score of
around 26 at the start of this time period and 18 at the
time of diagnosis, they reflect not the ideal of timely
diagnosis but the clinical reality that many patients
receive a diagnosis many years after the onset of AD-
dementia.
We implemented a cohort model where all individuals
follow either the standard pattern of decline or received
early intervention as described below. The cost of insti-
tutional care, and the relationship between MMSE and
direct non-institutional healthcare costs were reported
by Knapp & Prince in 2007 [30] based on the UK Na-
tional Health Service (NHS). These were inflated to
2011 costs using the PSSRU Hospital and Community
Health Services Index [31]. Costs and benefits were
discounted at a rate of 3.5% per year. The relationship
between probability of institutionalisation and MMSE
score was derived following Getsios et al’s methodology
[15], based on the national prevalence of AD-dementia
severities and the known severity of patients in institu-
tional care [32].
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Our baseline models calculated direct healthcare costs
over a ten-year timeframe, including the cost of the
diagnostic process where appropriate but excluding in-
direct costs ascribable to caregiver time. For all scenarios
involving an intervention we included the cost of a diag-
nostic assessment modelled on that recommended by
current UK dementia guidelines [33]. This cost a total of
£472.94 ($724; 2011 prices based on the Unit Costs of
Health and Social Care 2011 [31] and the NHS National
Schedule of Reference Costs Years 2011-12 [34]; see
Additional file 1: Table S1) and comprised a GP visit in-
cluding blood and biochemistry followed by either a CT
or MRI scan (50% probability of each), and a memory
clinic appointment comprising 60 minutes with a nurse,
45 minutes with a consultant psychiatrist, and with pos-
sible additional investigations, namely neuropsychology
(10% of patients) and SPECT (5% of patients).
Quality of life scores were combined with survival
rates to produce outcomes for quality-adjusted life
years (QALYs) which were ascribed a value of £25,000
($38,250). QALYs were derived based on a modifica-
tion of a published algorithm [35] that describes
QALYs in terms of MMSE score and independent ver-
sus institutional living. The full algorithm is as follows:
utility = 0.408 + (0.01 MMSE) - (0.159 if institutional-
ized) - (0.004 NPI) + (0.051 if living with caregiver).
We excluded the two final terms so the utility score
was based only on MMSE and institutionalisation. The
algorithm was used to ascertain utility for each MMSE
score and differences in resulting QALYs in the inter-
vention arm were ascribed based on MMSE score on a
monthly basis.
Modelling of interventions
Patients entering the early or standard intervention arms
were assumed to receive a hypothetical intervention
which varied with respect to the timing of the interven-
tion, the immediate change in MMSE, and the effect of
the intervention on disease course, which we modelled
simply as a temporary halt in cognitive deterioration.
Age-related mortality was applied from the point of early
intervention throughout the rest of the model [36].
A. Symptomatic treatment
This model was based on the likely effects of using
symptomatic treatments such as cholinesterase
inhibitors. The baseline case compared the
application of an intervention that immediately
improved MMSE by one point, and where the
beneficial effect wore off over 3 years, so that
3 years after intervention their MMSE score had
converged with the original course. This
intervention was applied at all points throughoutthe nine-year period and was compared against
intervention at the end of the nine years, i.e. at
actual time of diagnosis (standard intervention).
The baseline assumption was that the effect size of
intervention would be equal regardless of the time
at which the intervention was applied, and costs
and benefits were calculated initially using a ten
year horizon. The impact of these two parameters
was then assessed in sensitivity analyses. For all
scenarios the average age at model start was 75 years.B. Disease modification
There are various new potential disease-modifying
therapies for AD-dementia under research [37]. This
model assumed that a hypothetical intervention
(based on possible future treatment developments
rather than current available interventions), produced
no acute change in MMSE but prevented further
disease progression (change in MMSE score) for a
given period, after which the natural course of decline
would resume. This was compared against a model in
which no such intervention was applied (‘no
intervention’). The baseline case assumed that the
intervention produced a 12 month delay in disease
progression. Costs and benefits were calculated
over a ten year horizon, and a mean age of 75
was assumed at model start. The impact of each
of these parameters was then investigated in
subsequent analyses.Results
Symptomatic treatment
We first evaluated the effect of a symptomatic improve-
ment of one MMSE point, which declined over three
years and was applied eight years before standard inter-
vention. Figure 1A illustrates the difference in cognitive
profile between early and standard interventions under
this scenario. The economic benefits of intervention
were greatest when treatment was applied at the earliest
point in the model (i.e. 8 years prior to standard inter-
vention; see Figure 2). However, it is important to point
out that this models a hypothetical scenario (and, there-
fore, is not populated with data) using the assumption
that MMSE was improved by one point. At 8 years prior
to standard intervention, MMSE score is already high,
reflecting MCI-AD, and, therefore, the assumption of
one point improvement may overestimate that which be
made at the higher end of the MMSE scale. The results
should be interpreted with caution appropriate to a
hypothetical model. At this timepoint, the overall net
benefit of early intervention was £897 ($1372). There
was no apparent economic benefit in intervening less
than 3 years earlier than the standard, but in the period
between 3 and 9 years prior to standard intervention,
Figure 1 Effects on cognitive course of symptomatic and disease-modifying interventions applied 5, 8 or 1 year prior to a standard
diagnosis of Alzheimer’s disease. Panel A symptomatic intervention at 5 (top), 8 (middle), and 1 (lower) years; Panel B disease-modifying
intervention at 5 (top), 8 (middle), and 1 (lower) years.
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17% per year.
Maximum economic differences between standard
and early interventions, at −8 years, were: diagnostic
cost £293 (standard; $448) versus £473 (early; $724);
other healthcare costs £97,328 ($112,065) vs £96,608Figure 2 Cost-effectiveness of early intervention with a modest symp
and treatment. Panel A net benefit; B Gain in quality-adjusted life years (Q
efficacy reduces linearly over 3 years. Costs calculated over a 10-year horizo($147,810); gain in QALYs 4.246 vs 4.260 (Figure 2).
Average diagnostic cost was less for standard interven-
tion because some of those who would receive diagno-
sis under an early intervention protocol would not
survive long enough to receive it under a standard
intervention.tomatic treatment in the nine years prior to standard detection
ALYs); C incremental costs. Symptomatic effects = 1 MMSE point,
n. Mean cohort age at entry 75 years.
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regarding costing horizon and treatment efficacy we
repeated the model while varying these assumptions
(Figure 3). Reducing the costing horizon from 10 to
5 years after early intervention greatly increased the in-
cremental benefits of earlier intervention, because fewer
had the opportunity to benefit from standard detection.
Conversely, extending the costing horizon to 20 years
had relatively little effect (Figure 3A). Doubling or halv-
ing the treatment effect on MMSE produced corre-
sponding changes in net benefit that were greater in
absolute magnitude the earlier the treatment was applied
(Figure 3B). For a treatment that improved cognition by
only half an MMSE point, no net benefit was seen if
applied less than 7 years before standard intervention.
Net benefits were greater, and the benefits of early inter-
vention exacerbated, among older cohorts (Figure 3C),
where mortality effects meant that fewer would have
lived to receive the benefit of standard intervention.
Disease-modification
We then compared the effect of a hypothetical disease-
modifying intervention which halted cognitive deterior-
ation, against no such intervention. In the baseline
model, treatment halted deterioration for 12 months,
after which the natural progress of cognitive decline re-
sumed. Figure 1B illustrates the effect that this interven-
tion has on the cognitive course. The benefits were
greatest when the intervention occurred around two
years prior to standard intervention, at the point where
MMSE deterioration is greatest. Figure 4 shows the in-
cremental difference in healthcare costs, the gain in
QALYs and the net benefit for intervening across the
nine-year timeframe versus no intervention. The com-
parative costs for intervening at the optimal timepoint,
versus no such intervention, were: diagnostic cost £0
(no intervention) versus £472 (intervention) ($722);
other healthcare costs £121,790 ($186,339) vs £112,170
($171,620); gain in QALYs 2.454 vs 2.648, for an overall
net benefit of intervention of £13,996 ($21,414).Figure 3 Sensitivity of net benefits obtained under a symptomatic tre
A: results when costing over 5, 10 and 20 years; Panel B: result of doubling
cohort age at model start.To test sensitivity to the assumptions regarding cost-
ing horizon, treatment efficacy and age of cohort we
again repeated the model while varying each of these pa-
rameters (Figure 5). All three considerably affected the
magnitude of net benefit observed. In contrast to the
symptomatic model, net benefits were greater over longer
costing horizons (Figure 5A) and time of intervention had a
greater impact on net benefit when considering the shortest
costing horizon (5 years). Treatment efficacy, modelled as
length of delay in cognitive deterioration had a particularly
large effect on cost-effectiveness (Figure 5B). For example, a
treatment that delayed deterioration by 36 months and that
was applied 2 years prior to standard intervention provided
a net benefit of £37,098 ($56,760). Net benefits were greater,
and the effect of early intervention exacerbated, among
younger cohorts, where mortality over the post-diagnostic
period would be lower.
Comparison of the effect of timing of intervention for
symptomatic versus disease-modifying treatments
The two intervention scenarios had very different ef-
fects on the overall course of cognitive function. For
the symptomatic treatment, the benefits of interven-
tion were inherently time-limited and roughly equal in
magnitude with respect to the overall effect on cogni-
tive course (area under the curve in Figure 1A). In con-
trast, the nature of the disease-modifying intervention
was such that the immediate effect of the intervention
was driven by the nature of the cognitive decline func-
tion at the time of intervention, and the majority of the
effect on cognition was seen relatively late in the decline
curve (Figure 1B). In absolute terms, the maximum net
benefit of the disease modifying intervention modelled here
was fifteen times greater than for the modelled symptom-
atic treatment.
Discussion
In this study we utilised the known natural history of cogni-
tive decline in Alzheimer’s disease to estimate the health
economic impact of earlier intervention. We modelled twoatment model to costing horizon and treatment effect size. Panel
or halving of treatment effect on MMSE score; Panel C: effect of mean
Figure 4 Cost-effectiveness of early intervention with a hypothetical disease-modifying treatment in the nine years prior to standard
detection and treatment. Panel A net benefits; B Gain in quality-adjusted life years (QALYs); C incremental costs. Treatment effect is a 12-month
halt in cognitive deterioration. Costs calculated over a 10-year horizon. Mean cohort age at entry 75 years. Panel A, net benefits; Panel B, gain in
quality-adjusted life years (QALYs); Panel C cost savings. Treatment effect is a 12-month halt in cognitive deterioration. Costs calculated over a
10-year horizon. Mean cohort age at entry 75 years.
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similar to those seen for cholinesterase inhibitors, the
other a disease-modifying intervention that delayed
cognitive deterioration for a period of time. In both
cases, results showed that optimally timing an inter-
vention could significantly affect its economic benefits.
For the symptomatic treatment, the economic benefits
were greater the earlier the intervention was applied; in
contrast the disease-modifying intervention was most cost-
effective when applied relatively late in the course.
These differences in optimal timing between symptom-
atic and disease-modifying models can be explained by the
effects of mortality on post-diagnostic healthcare costs and
by the changing rate of cognitive decline throughout the
disease course. For the symptomatic intervention, treat-
ment benefits are immediate and decrease over a fixed time
period. Intervention is consequently most effective when
applied at the earliest possible timeframe, so that the great-
est number of individuals benefit from the intervention
before any loss to mortality. However the effect of this
intervention is relatively small because it is inherently time-
limited. In contrast, in the disease-modifying model, while
there is no immediate impact, the effect of intervention is
to permanently shift the curve of cognitive decline. As a re-
sult, the effect on both healthcare costs and QALYs isFigure 5 Sensitivity of net benefits obtained through a hypothetical d
and age of cohort. Panel A: results when costing over 5, 10 and 20 years; Pan
months delay in deterioration in MMSE score; Panel C: effect of mean cohort agconsiderably larger. Under this scenario, intervention was
most economically beneficial when applied around two
years prior to the time of standard diagnosis. This is the
period during which MMSE decline is most rapid: interven-
ing either earlier or later than this reduces the costs saved
by delaying cognitive decline.
Other health economic models of disease modifying
treatments have also estimated higher costs with DMT
over time, due to additional costs of DMT and the in-
creased survival with DMT [38].
Of the two interventions, the results from the symp-
tomatic model are more immediately applicable because
moderately effective symptomatic treatments are already
available in the UK for patients with mild to severe
AD -dementia (MMSE of 26 or below). In this cohort,
individuals already had a mean MMSE score indicating
AD-dementia treatment up-to nine years before diagno-
sis, so these results are in one sense supporting not
‘early’, but rather ‘on time’ intervention. While we have
not included treatment costs in the model, generic AD-
dementia drugs now cost just pennies per day. These re-
sults therefore support previous analyses demonstrating
the cost-effectiveness of intervention and treatment
using symptomatic treatments in the NHS, and extend
this by arguing that intervention will be more cost-isease-modifying treatment to costing horizon, treatment effect
el B: result of increased and decreased treatment effect, as expressed in
e at model start.
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the majority of patients.
The disease-modifying results should not be inter-
preted to mean that we can wait until frank dementia
before intervening. On the contrary, to maximise the
cost-effectiveness of a disease-modifying strategy, the
benefits of such a treatment must be being felt before
patients hit the period of rapid decline that precedes a
diagnosis in this cohort. In order to prevent this precipi-
tous decline it will, at a minimum, be necessary to detect
and closely monitor individuals with milder cognitive
impairment so that intervention can be certain to occur
prior to that point of inflection. In all likelihood, the
mode of action of such an intervention, be it a lifestyle
prevention strategy or anti-amyloid immunisation, would
probably need intervention to start many years or decades
earlier in order to have an impact on cognitive course.
Our model included full direct health and social care
costs and the cost of the diagnostic procedure but ex-
cluded any costs associated with informal caregiver time
[39,40], and, importantly, the cost of the intervention it-
self. This might range from a few pounds per month for
a generic drug such as a cholinesterase inhibitor to many
thousands for a future biological therapy. Alternatively,
modification of disease course and its impact, could
potentially be obtained from non-pharmacological strat-
egies such as lifestyle intervention which might be required
decades earlier (i.e. as a primary prevention strategy) in
order to prevent the disease process from occurring [41].
Although excluding the cost of informal care narrows the
viewpoint somewhat, excluding these costs takes a conser-
vative approach. Including caregiver costs would cause the
results to be more favourable towards early detection. A
sensitivity analysis demonstrated that the inclusion of a cost
associated with the intervention has a linear impact on the
model’s findings. That is, if the cost of the intervention is
£50, then the total cost savings associated with early detec-
tion will be reduced by £50. If the cost of the intervention
is £200, the cost savings are reduced by £200.
We did not include in our models a specific cost of
treatment, so these results provide a framework for esti-
mating the likely bearable costs to the UK health system
for a sufficiently effective anti-dementia intervention.
The results show that cost-effectiveness might be achieved
with either a cheap symptomatic treatment or a more
expensive disease-modifying one. The treatment effects
modelled here were purposefully modest and reflect the
relatively small effects achieved thus far in both approved
and developing compounds. While both the healthcare
costs and QALY values used here are taken from the UK
system, the principles are likely to apply widely within
European and North American countries, where under-
diagnosis is common [17-19] and where any intervention
which improved the function of AD-dementia patientswould be expected to have a proportionally similar effect
on healthcare costs [42].
An important limitation of the model is the assump-
tion that the efficacy of the intervention does not de-
pend on when it is applied, either with respect to illness
severity, or to cohort age. At present little data exists ad-
dressing this for existing treatments, although for future
anti-amyloid therapies intervention is likely to be more
effective when applied earlier in disease course. Age at
treatment start is particularly important because at the
older ages, mortality plays an increasing role in exaggerat-
ing the economic differences between early and standard
intervention. In the absence of published data, we ignored
the effect of treatment on survival, whilst in reality disease-
modifying interventions, in particular, would be expected to
play a role in reducing mortality. All of these limitations are
conservative in nature and would lead, if anything, to an
underestimation by the present model of the benefits of
earlier intervention.
The model also does not take into account the pos-
sible effect of false positives. As diagnoses of AD-
dementia shifts to earlier disease states the difference
between pathological symptoms and normal age-related
cognitive decline is likely to be subtle, with the potential for
greater diagnostic uncertainty, leading to an increased risk
of a false positive diagnosis (Albert, 2011). Due to a lack of
data this was not included in the model; however the likely
impact of including this would be that in earlier diagnosis
there are more false positives, leading to treatment costs
increasing, while no extra benefit is incurred. This should
be considered in future studies and when translating our
analyses.
Conclusions
In summary, we demonstrate that for both symptomatic
and disease-modifying interventions, timing is crucial in
determining the economic benefits of a treatment,
even leaving aside the issue of treatment efficacy. Early
intervention is clearly indicated for current symptomatic
treatments, which are likely to be most cost-effective when
applied as early as it is possible to diagnose AD-
dementia. For a disease-modifying intervention, maximal
cost-effectiveness would be achieved by intervening early
enough to anticipate the point at which cognition begins
a rapid decline. Taken together, these results suggest that
cost-effective early detection and intervention should be
an achievable goal in earlier stages of AD (MCI-AD), and
that a range of different intervention effects and costs
might be manageable or even beneficial in terms of over-
all healthcare costs. Public policy including screening,
diagnostic and prescribing guidelines should aim to re-
flect the optimal cognitive stage for cost-effective inter-
vention, which will be several years prior to current
standard practice.
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